Navigation Links
A prescription cream for unwanted facial hair,,

VaniqaT is a prescription drug which was approved by the FDA in the United States on July 31, 2000 for treating excessive facial hair in women, which is often part of hirsutism.

It may be a welcome alternative for women for whom this problem is considered serious enough to warrant tweezing, waxing, or shaving at least once a week for hair removal. Vaniqa is actually not a brand new drug, but rather a new topical-use version of the older drug eflornithine (brand name Ornidyl).

Vaniqa, like Viagra, is considered to be a "lifestyle drug", a drug which generally improves our quality of life, but is not considered to be essential for good health. Vaniqa is the first prescription drug approved in the United States to treat this condition. It was effective, compared to placebo, in approximately 25% of women who used it during the pre-release clinical trials. Although Vaniqa currently appears have few side effects, when used as directed, post-release experience often modifies the safety profile for new drugs.
'"/>




Page: 1

Related medicine news :

1. Patients Pressure Would Result In Overprescription
2. TV drug commercials prompt prescriptions
3. Status of some prescription drugs
4. Abuse of prescription drugs among youths on the rise
5. Bush’s new prescription drug plan, a complex puzzle for the citizen
6. Many Nonprescription Cough Medicines Proves Ineffective
7. A urine test for ease in prescription of drugs and therapies
8. Doctors to give complete information on prescriptions to patients
9. U S Government Allows Non-prescription Diet Pill
10. Lifestyle changes not prescription drugs to fight diabetes, say scientists
11. Sun burns treated with creams
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/5/2016)... ... December 05, 2016 , ... Routine ... measurements are consistently correct. However, regular performance testing is often neglected because ... a solution: SmartCal™ . This innovative test substance offers a fast ...
(Date:12/4/2016)... (PRWEB) , ... December 03, 2016 , ... ... organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community ... hosted its first Swirl: A Wine Tasting Event in New York City, with ...
(Date:12/4/2016)... ... December 04, 2016 , ... "Pro3rd Displace ... animation styles with unique displacement design elements," said Christina Austin - CEO of ... Choose from a variety of design styles that include both left aligned and ...
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen and Sara ... speak at the American Conference Institute’s 21st Drug & Medical Device Litigation Conference ... Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device & ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Advanced Inc., a ... has appointed Jason Bice, CPA, MBA to serve as Advanced Inc.’s Chief Financial Officer, ... Inc. , Jason brings extensive financial and operational leadership experience to Advanced Inc. ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , December 5, 2016 BioLineRx ... in-licensing and developing promising therapeutic candidates, presents positive Phase 2a ... the Company,s leading oncology platform at the ongoing 58th American ... San Diego, California . ... , , ...
(Date:12/5/2016)... The global  non-invasive prenatal testing market  is anticipated ... by Grand View Research, Inc. Evolution of prenatal testing in the form ... screening and invasive diagnostic testing to determine the likelihood of fetal abnormality ... forecast period. Continue Reading ... ...
(Date:12/4/2016)... -- Johnson & Weaver, LLP announces that a class action ... Holdings, Inc. (NYSE: ZBH )  securities during the ... "Class Period"). Zimmer Biomet provides musculoskeletal healthcare products ... such as knee and hip reconstructive products. ... , , ...
Breaking Medicine Technology: